Voyager Therapeutics (NASDAQ:VYGR) Insider Sells $15,694.24 in Stock

Voyager Therapeutics, Inc. (NASDAQ:VYGR) insider Todd Alfred Carter sold 4,174 shares of the stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $3.76, for a total transaction of $15,694.24. Following the transaction, the insider directly owned 145,718 shares in the company, valued at approximately $547,899.68. The trade was a 2.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Todd Alfred Carter also recently made the following trade(s):

• On Tuesday, February 10th, Todd Alfred Carter sold 3,525 shares of Voyager Therapeutics stock. The stock was sold at an average price of $3.85, for a total transaction of $13,571.25.

Voyager Therapeutics Trading Down 3.1%

Shares of Voyager Therapeutics stock opened at $4.10 on Friday. Voyager Therapeutics, Inc. has a twelve month low of $2.64 and a twelve month high of $5.55. The firm has a market capitalization of $227.96 million, a PE ratio of -1.90 and a beta of 1.30. The firm’s 50-day moving average price is $3.86 and its 200 day moving average price is $4.12.

Institutional Investors Weigh In On Voyager Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in VYGR. Barclays PLC grew its holdings in Voyager Therapeutics by 2.5% in the 4th quarter. Barclays PLC now owns 162,112 shares of the company’s stock valued at $637,000 after buying an additional 4,003 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its position in shares of Voyager Therapeutics by 9.6% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 61,775 shares of the company’s stock valued at $249,000 after acquiring an additional 5,422 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Voyager Therapeutics by 1.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 303,133 shares of the company’s stock valued at $1,191,000 after acquiring an additional 5,560 shares during the last quarter. American Century Companies Inc. grew its holdings in shares of Voyager Therapeutics by 5.1% in the second quarter. American Century Companies Inc. now owns 138,269 shares of the company’s stock valued at $430,000 after purchasing an additional 6,748 shares during the period. Finally, Jain Global LLC increased its position in Voyager Therapeutics by 44.1% during the third quarter. Jain Global LLC now owns 28,104 shares of the company’s stock worth $131,000 after purchasing an additional 8,600 shares during the last quarter. Institutional investors and hedge funds own 48.03% of the company’s stock.

Analyst Ratings Changes

VYGR has been the topic of a number of research analyst reports. Wedbush reaffirmed an “outperform” rating and issued a $8.00 price target on shares of Voyager Therapeutics in a research note on Tuesday, November 11th. Wall Street Zen lowered Voyager Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 21st. Finally, HC Wainwright lowered their target price on shares of Voyager Therapeutics from $30.00 to $25.00 and set a “buy” rating on the stock in a research note on Wednesday, November 12th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $13.75.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.